Verzenios ® (abemaciklib)

För fullständig produktresumé för Verzenios se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Verzenios® ▼ (abemaciclib): Biopsier i kliniska studier av metastatisk bröstcancer

Tumörvävnad samlades in och förvarades vid randomisering i Verzenios (abemaciclib) pivotala studier MONARCH 2 och MONARCH 3

Summary

The pivotal study MONARCH 2 tested Verzenios in combination with fulvestrant, the privotal study MONARCH 3 tested Verzenios in combination with aromatase inhibitors.1

In the MONARCH 2 study, archived tumor tissue was requested at the time of patient randomization. Blood and plasma samples for biomarker analysis were collected at baseline. There were no additional samples collected from patients for biomarker analysis during the study.2

In the MONARCH 3 study, archived tumor tissue was requested at the time of patient randomization. Blood and plasma samples for biomarker analysis were collected at baseline, after initiation of treatment, and at the post discontinuation visit in patients with progressive disease.2

References

1. Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M06 19


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss